Kotyza Jaromir
Institute of Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilzen, Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Mar;161(1):41-49. doi: 10.5507/bp.2016.062. Epub 2017 Jan 6.
Chemokines are chemotactic cytokines produced by leukocytes and other types of cells including tumor cells. Their action is determined by the expression of cognate receptors and subsequent signaling in target cells, followed by the modulation of cytoskeletal proteins and the induction of other responses. In tumors, chemokines produced by neoplastic/stroma cells control the leukocyte infiltrate influencing tumor growth and progression. Tumor cells also express functional chemokine receptors responding to chemokine signals, promoting cell survival, proliferation and metastasis formation. Chemokines may be detected in serum of cancer patients, but due to the paracrine nature of these molecules, more significant concentrations are found in the tumor adjacent, non-vascular fluids, collectively called tumor proximal fluids. This review summarizes the expression of CC and CXC chemokines in these fluids, namely in interstitial fluid, pleural, ascitic, and cyst fluids, but also in urine, saliva, cerebrospinal fluid, cervical secretions and bronchoalveolar lavage fluid. Most comparative clinical studies reveal increased chemokine levels in high-grade tumor proximal fluids rather than in low-grade tumors and benign conditions, indicating shorter survival periods. The data confirm peritumoral fluid chemokines as sensitive diagnostic and prognostic markers, as well as offer support for chemokines and their receptors as potential targets for antitumor therapy.
趋化因子是由白细胞以及包括肿瘤细胞在内的其他类型细胞产生的趋化性细胞因子。它们的作用取决于同源受体的表达以及靶细胞中的后续信号传导,随后是细胞骨架蛋白的调节和其他反应的诱导。在肿瘤中,肿瘤/基质细胞产生的趋化因子控制白细胞浸润,影响肿瘤的生长和进展。肿瘤细胞也表达对趋化因子信号有反应的功能性趋化因子受体,促进细胞存活、增殖和转移形成。趋化因子可在癌症患者的血清中检测到,但由于这些分子的旁分泌性质,在肿瘤邻近的非血管性液体(统称为肿瘤近端液体)中发现的浓度更高。本综述总结了CC和CXC趋化因子在这些液体中的表达,即组织间液、胸水、腹水和囊液中,也包括尿液、唾液、脑脊液、宫颈分泌物和支气管肺泡灌洗液中的表达。大多数比较性临床研究表明,高级别肿瘤近端液体中的趋化因子水平高于低级别肿瘤和良性疾病,提示生存期较短。这些数据证实肿瘤周围液体趋化因子是敏感的诊断和预后标志物,并为趋化因子及其受体作为抗肿瘤治疗的潜在靶点提供了支持。